Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mucic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.66 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.66 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.66 |
| ▸ | MAOA | P21397 | 1/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.66 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.66 |
| ▸ | ALPI | P09923 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | XIAP | P98170 | 1/20 | 0.55 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | LAP3 | P28838 | 2/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mucic Acid SCHEMBL28326693 | 1.00 | TAAR1 (0.66) | TAAR1SLC6A4SLC6A2MAOASLC6A3 | |
| Mucic Acid SCHEMBL578988 | 1.00 | TAAR1 (0.66) | TAAR1SLC6A4SLC6A2MAOASLC6A3 | |
| Levamfetamine SCHEMBL1320449 | 0.93 | TAAR1 (0.70) | TAAR1SLC6A4SLC6A2MAOASLC6A3 | |
| Dextroamphetamine SCHEMBL31637552 | 0.93 | TAAR1 (0.70) | TAAR1SLC6A4SLC6A2MAOASLC6A3 | |
| Amphetamine SCHEMBL6251827 | 0.93 | TAAR1 (0.70) | TAAR1SLC6A4SLC6A2MAOASLC6A3 | |
| Dextroamphetamine SCHEMBL6251824 | 0.93 | TAAR1 (0.70) | TAAR1SLC6A4SLC6A2MAOASLC6A3 | |
| Gluconic Acid SCHEMBL29102204 | 0.91 | SLC6A4 (0.54) | TAAR1SLC6A4SLC6A2MAOASLC6A3 | |
| Dextroamphetamine SCHEMBL8505954 | 0.87 | TAAR1 (0.61) | TAAR1SLC6A4SLC6A2MAOASLC6A3 | |
| Amphetamine SCHEMBL29127738 | 0.85 | TAAR1 (0.76) | TAAR1SLC6A4SLC6A2MAOASLC6A3 | |
| Mucic Acid SCHEMBL27988518 | 0.84 | SLC7A5 (0.79) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 600 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544385-B2 | Combination drug therapies for CNS disorders | JAVED MOHAMMAD (US) | 2026-02-10 | — | — | US | claimed |
| EP-4683622-A1 | NON-DISTILLATIVE PROCESS FOR MANUFACTURING HIGH PURITY AMPHETAMINES | Pharmapotheca A, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| US-12534428-B2 | Non-distillative process for manufacturing high purity amphetamines | Pharmapotheca A, Inc. (US) | 2026-01-27 | — | — | US | claimed |
| US-20250352538-A1 | PHARMACEUTICAL RESINATE COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF | RHODES PHARMACEUTICALS LP (US) | 2025-11-20 | — | — | US | claimed |
| US-20250206698-A1 | Process for Making Lisdexamfetamine Dimesylate | Pharmapotheca A, Inc. | 2025-06-26 | — | — | US | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-12208068-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | Pharmapotheca A Inc. (US) | 2025-01-28 | — | — | US | claimed |
| US-20240286993-A1 | Non-distillative Process for Manufacturing High Purity Amphetamines | Pharmapotheca A, Inc. | 2024-08-29 | — | — | US | claimed |
| WO-2024175957-A1 | NON-DISTILLATIVE PROCESS FOR MANUFACTURING HIGH PURITY AMPHETAMINES | Pharmapotheca A, Inc. (US) | 2024-08-29 | — | — | WO | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| WO-2004028509-A1 | SUSTAINED RELEASED DELIVERY OF AMPHETAMINE SALTS | SHIRE LABORATORIES, INC. (US) | 2004-04-08 | — | — | WO | claimed |
| US-20040059002-A1 | Sustained release delivery of amphetamine salts | SHIRE LABORATORIES, INC. | 2004-03-25 | — | — | US | claimed |
| US-20030194439-A1 | Pharmaceutical dosage form for pulsatile delivery of methylphenidate | MIDHA KAMAL K (BM) | 2003-10-16 | — | — | US | claimed |
| US-6605300-B1 | For treatment of ADHD | SHIRE LABORATORIES, INC. | 2003-08-12 | — | — | US | claimed |
| US-6555136-B2 | First, second and optionally third dosage units, with each dosage unit having a different drug release profile. | PHARMAQUEST, LTD. (BM) | 2003-04-29 | — | — | US | claimed |
| US-20020058061-A1 | Pharmaceutical dosage form for pulsatile delivery of methylphenidate | MIDHA KAMAL K (CA) | 2002-05-16 | — | — | US | claimed |
| US-6384020-B1 | AMPHETAMINE BASE AND LACTITOL WITH MICROCRYSTALLINE CELLULOSE | SHIRE LABORATORIES, INC. | 2002-05-07 | — | — | US | claimed |
| EP-1165054-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF METHYLPHENIDATE | Pharmaquest Limited (BM) | 2002-01-02 | — | — | EP | claimed |
| US-6217904-B1 | MIXTURES; ADMINISTERING IN CYCLES | PHARMAQUEST LTD. (BM) | 2001-04-17 | — | — | US | claimed |
| WO-2000059479-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF METHYLPHENIDATE | PHARMAQUEST LTD. (BM) | 2000-10-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544385-B2 | Combination drug therapies for CNS disorders | SLC6A3, SLC6A2, SLC18A2 | SLC6A2 2/4885SLC6A3 1/4885TAAR1 63/4885 |
| US-20250206698-A1 | Process for Making Lisdexamfetamine Dimesylate | COMT, MGAM, ADH5 | SLC6A2 48/4885SLC6A3 10/4885TAAR1 448/4885 |
| US-20240286993-A1 | Non-distillative Process for Manufacturing High Purity Amphetamines | AASDHPPT, AADAT, SLC6A3 | SLC6A2 30/4885SLC6A3 3/4885TAAR1 133/4885 |
| US-12534428-B2 | Non-distillative process for manufacturing high purity amphetamines | SMS, SRMS, SRM | SLC6A2 12/4885SLC6A3 6/4885TAAR1 28/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | SLC6A2 1338/4885SLC6A3 1329/4885TAAR1 142/4885 |
| US-12208068-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | SLC6A3, CES2, SLC6A2 | SLC6A2 3/4885SLC6A3 1/4885TAAR1 37/4885 |
| US-20030194439-A1 | Pharmaceutical dosage form for pulsatile delivery of methylphenidate | SLC18A1, SLC6A3, CRH | SLC6A2 10/4885SLC6A3 2/4885TAAR1 554/4885 |
| US-20020058061-A1 | Pharmaceutical dosage form for pulsatile delivery of methylphenidate | SLC18A1, SLC6A3, CRH | SLC6A2 10/4885SLC6A3 2/4885TAAR1 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.